Matthew Angel's most recent trade in Tempest Therapeutics Inc was a trade of 231,482 Common Stock done at an average price of $2.2 . Disclosure was reported to the exchange on March 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tempest Therapeutics Inc | Matthew Angel | Director, CEO and President, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.16 per share. | 24 Mar 2026 | 231,482 | 231,482 | - | 2.2 | 500,001 | Common Stock |
| Tempest Therapeutics Inc | Matthew Angel | Director, CEO and President, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 269,621 | 269,621 | - | - | Employee Stock Option (right to buy) | |
| Eterna Therapeutics Inc | Matthew Angel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 132,003 | 132,003 | - | - | Stock Option (right to buy) | |
| Eterna Therapeutics Inc | Matthew Angel | Director, Interim President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 2,487,003 | 2,487,003 | - | - | Stock Option (right to buy) |